Beaird Harris Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$759K Buy
3,016
+4
+0.1% +$861 0.05% 79
2026
Q1
$655K Buy
3,012
+4
+0.1% +$887 0.04% 84
2025
Q4
$687K Sell
3,008
-87
-3% -$19.8K 0.05% 81
2025
Q3
$717K Buy
3,095
+35
+1% +$7.13K 0.05% 79
2025
Q2
$568K Buy
3,060
+31
+1% +$5.76K 0.04% 86
2025
Q1
$635K Sell
3,029
-96
-3% -$18.7K 0.05% 73
2024
Q4
$555K Buy
3,125
+393
+14% +$72.3K 0.05% 82
2024
Q3
$539K Buy
2,732
+675
+33% +$126K 0.05% 84
2024
Q2
$353K Sell
2,057
-56
-3% -$9.28K 0.03% 95
2024
Q1
$385K Buy
2,113
+191
+10% +$32.9K 0.04% 83
2023
Q4
$298K Buy
1,922
+46
+2% +$6.71K 0.03% 87
2023
Q3
$280K Buy
1,876
+77
+4% +$11.3K 0.03% 80
2023
Q2
$242K Buy
1,799
+5
+0.3% +$733 0.03% 89
2023
Q1
$286K Sell
1,794
-64
-3% -$9.79K 0.05% 75
2022
Q4
$300K Buy
1,858
+73
+4% +$11.2K 0.06% 71
2022
Q3
$240K Buy
1,785
+462
+35% +$66.3K 0.05% 72
2022
Q2
$203K Sell
1,323
-1,252
-49% -$191K 0.06% 67
2022
Q1
$417K Buy
2,575
+4
+0.2% +$581 0.15% 52
2021
Q4
$348K Buy
+2,571
New +$304K 0.13% 79

Other funds holding ABBV

Beaird Harris Wealth Management's ABBV Position: Q2 2026 in Review

Beaird Harris Wealth Management increased its AbbVie (ABBV) stake by 0.13% in Q2 2026, buying an estimated $861 and bringing the position to 3,016 shares worth $759K. The position accounts for 0.05% of the portfolio, ranked #79.

Beaird Harris Wealth Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Beaird Harris Wealth Management held 3,016 shares of AbbVie worth $759K as of Q2 2026.
  • Beaird Harris Wealth Management bought 4 AbbVie shares in Q2 2026, an estimated $861.
  • AbbVie made up 0.05% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #79 holding.
  • Beaird Harris Wealth Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.